Sesen Bio (SESN) announced that it has initiated a process to review strategic alternatives

POTENTIAL DEAL DETAILS

Sesen Bio (SESN), a late-stage clinical company developing targeted fusion protein therapeutics for the treatment of patients with cancer, announced that it has initiated a process to review strategic alternatives with the goal of maximizing shareholder value.

Update(s):

September 21, 2022: Sesen Bio, Inc. (SESN) and Carisma Therapeutics Inc., a privately held, clinical stage biopharmaceutical company focused on discovering and developing innovative immunotherapies, announced that they have entered into a definitive merger agreement to combine the companies in an all-stock transaction.

Disclaimer: Our intent with this section of the website is to present potential deals that appear to be in the pipeline. These potential deals are ones where i) the company has indicated that it is "seeking strategic alternatives", ii) there has been an unsolicited bid for a company as mentioned in a press release by the company or iii) news about the deal has been published by a leading news organization like The Wall Street Journal, The New York Times, Bloomberg, Financial Times, The Washington Post, Reuters and The Associated Press. As best as possible we will try to avoid baseless rumors. There is a high probability that many of these potential deals may not materialize and if they do, the terms of the deal may be different from what was initially reported. Please do your own due diligence before buying or selling any securities mentioned on this website. We do not warrant the completeness or accuracy of the content or data provided.